DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7,749,992 B2 Cao Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7,749,992 B2 Cao Et Al USOO7749992B2 (12) United States Patent (10) Patent No.: US 7,749,992 B2 Cao et al. (45) Date of Patent: Jul. 6, 2010 (54) COMPOUNDS AND METHODS FOR 5,602,122 A 2/1997 Flynn et al. TREATING DSLPIDEMA 5,622,947 A 4/1997 Ogawa et al. 6,090,824 A 7/2000 Bernstein et al. (75) Inventors: Guoqing Cao, Carmel, IN (US); Ana 6,096,735 A 8 2000 Ogawa et al. Maria Escribano, Alcobendas-Madrid 6,140,343 A 10/2000 DeNinno et al. (ES); Maria Carmen Fernandez, 6,147,089 A 11/2000 DeNinno et al. Alcobendas-Madrid (ES); Todd Fields, 6,147,090 A 11, 2000 DeNinno et al. Indianapolis, IN (US); Douglas Linn 6, 197,786 B1 3/2001 DeNinno et al. Gernert, Indianapolis, IN (US); R R 58: N et al - K - aO a shortly to Troy, NY 6,586.448 B1 7/2003 DeNinno et al. s s 6,689,897 B2 2/2004 Damon et al. NAGA S. (US Nath: Bryan 6,962.931 B2 11/2005 Gumkowski et al. antlo, Brownsburg, N (US); Eva 2002/00725 14 A1 6/2002 Brendel et al. Maria Martin De La Nava, 2002/0103225 A1 8/2002 Curatolo et al. Alcobendas-Madrid (ES); Ana Isabel 2003/0198674 A1 10, 2003 Curatolo et al. Mateo Herranz, Algobendas-Madrid 2004/0082609 A1 4/2004 Ghosh et al. (ES); paniel Ray Mayhugh, Carmel, IN 2004/0204450 A1 10, 2004 Bechle et al. (US); Xiaodong Wang, Carmel, IN (US) 2005/0059810 A1 3, 2005 Maeda et al. (73) Assignee: Eli Lilly and Company, Indianapolis, 2005/0234212 A1 10/2005 Depuydt et al. IN (US) 2006/010O239 A1 5/2006 Nagasaki et al. (*) Notice: Subject to any disclaimer, the term of this 2007/0173526 A1 7, 2007 Bell et al. patent is extended or adjusted under 35 2007/0208003 A1 9, 2007 Bell et al. U.S.C. 154(b) by 994 days 2007/0244095 A1 10, 2007 Chen et al. M YW- 2008/0269284 A1 10, 2008 Escribano et al. (21) Appl. No.: 10/574,649 (22) PCT Filed: Oct. 7, 2004 (86). PCT No.: PCT/US2004/030907 FOREIGN PATENT DOCUMENTS EP 1125929 11, 2000 S371 (c)(1), JP 1997 2214746 A 8, 1997 (2), (4) Date: Mar. 30, 2006 WO WOO1/4019.0 A1 6, 2001 (87) PCT Pub. No.: WO2005/037796 WO WO 2005/033O82 A2 4/2005 WO WO 2005/033O82 A3 4/2005 PCT Pub. Date: Apr. 28, 2005 (65) Prior Publication Data OTHER PUBLICATIONS US 2007/O254869 A1 Nov. 1, 2007 Related U.S. ApplicationO O Data Bisgaier et al. J of Lipid Res. 1993, 34, 1625-1634. Primary Examiner Brenda L. Coleman (60) Eyinal application No. 60/509,736, filed on Oct. (74) Attorney, Agent, or Firm—James B. Myers; Francis O. s Ginah (51) Int. Cl. A6IP3/06 (2006.01) (57) ABSTRACT A6IP 9/10 (2006.01) A6 IK3I/55 (2006.01) CO7D 22.3/4 (2006.01) Compounds of formula I CO7D 22.3/6 (2006.01) CO7D 223/32 (2006.01) 4 CO7D 225/06 (2006.01) R R3 CO7D 403/04 (2006.01) CO7D 403/2 (2006.01) 1N CO7D 405/06 (2006.01) (R)- (CH2) CO7D 405/2 (2006.01) 4NuS (R2) CO7D 413/04 (2006.01) N CO7D 49/04 (2006.01) (CHR) R1 (52) U.S. Cl. .................................. 514/213.01:54.0/593 N1 (58) Field of Classification Search ............ 514/213.01; S lication file f 1 hhi 540,593 whereinn, m, p, q, y, R. R. R. R. R. and Rare as defined ee application file for complete search history. herein and their pharmaceutical compositions and methods of (56) References Cited use are disclosed as useful for treating artherosclerosis and its sequelae. U.S. PATENT DOCUMENTS 5,484,783 A 1/1996 Flynn et al. 14 Claims, No Drawings US 7,749,992 B2 1. 2 COMPOUNDS AND METHODS FOR have relatively low HDL cholesterol, whereas mice and rats TREATING DSLIPIDEMA do not express CETP and carry nearly all their cholesterol in HDL. Further more, transgenic expression of CETP in mice REFERENCE TO RELATED APPLICATIONS results in significantly reduced HDL cholesterol levels and developed severe atherosclerosis compared to control mice This application is submitted as a United States national (K. R. Marotti et al., (1993) Severe atherosclerosis in trans phase entry, pursuant to 35 U.S.C S371, of PCT/US2004/ genic mice expressing simian cholesteryl ester transfer pro 030907, filed on Oct. 7, 2004, which claims the benefit of U.S. tein. Nature: 364, 73-75). Expression of human CETP in provisional patent application Ser. No. 60/509,736, filed Oct. Dahl salt-sensitive hypertensive rats led to spontaneous com 8, 2003, which is incorporated by reference herein. 10 bined hyperlipidemia, coronary heart disease and decreased survival (V. L. M. Herrera et al., (1999) Spontaneous com FIELD OF THE INVENTION bined hyperlipidemia, coronary heart disease and decreased Survival in Dahl salt-sensitive hypertensive rats transgenic for The current invention relates to the fields of medicinal human cholesteryl ester transfer protein. Nature Medicine: 5, organic chemistry, pharmacology, and medicine. Further, the 15 current invention relates to a group of compounds that dem 1383-1389). onstrate utility for treating pathological states due to dyslipi Antibodies either directly injected into the plasma or gen demia erated through vaccine injection can effectively inhibit CETP activity in hamsters and rabbits resulting in elevated HDL BACKGROUND OF THE INVENTION cholesterol (C. W. Rittershaus, (1999) Vaccine-induced anti bodies inhibit CETP activity in vivo and reduce aorticlesions Coronary heart disease (CHD) is one of the major causes of in a rabbit model of atherosclerosis. Furthermore, antibody morbidity and mortality worldwide. Despite attempts to neutralization of CETP in rabbits has been shown to be anti modify risk factors such as obesity, Smoking, lack of exercise, atherogenic (Arterio. Thromb. Vasc, Biol. 20, 2106-2112: G. and treatment of dyslipidemia with dietary modification or 25 F. Evans et. al., (1994) Inhibition of cholesteryl ester transfer drug therapy, CHD remains the most common cause of death protein in normocholesterolemic and hypercholesterolemic in the U.S. Over 50% of all CHD deaths are due to underlying hamsters: effects on HDL Subspecies, quantity, and apolipo atherosclerotic coronary heart disease. protein distribution.J. Lipid Research. 35, 1634-1645). How Dyslipidemia is a major risk factor for CHD. Low plasma ever, antibody and/or vaccine therapy is not currently a viable levels of high density lipoprotein (HDL) cholesterol with 30 option for the treatment of large populations of patients in either normal or elevated levels of low density (LDL) choles need of treatment for dyslipidemia and resultant or associated terol is a significant risk factor for developing atherosclerosis disease state manifestations. and associated coronary artery disease in humans. Indeed, Benzazepines have been reported as useful for certain several studies on lipoprotein profiles of CHD patients have therapeutic purposes. For example, Kondo et all teaches the shown that about 50% of the CHD patients have cholesterol 35 use of certain benzazepines derivatives as potent orally active levels that are considered to be in the normal range (<200 non-peptide arginine vasopressin V2 receptor antagonists, mg/dl). Furthermore, these studies found low HDL choles see Kondo et al., 7-chloro-5-hydroxy-1-2-methylbenzoy terol in about 40% of the normo-cholesterolemic CHD lamino)benzoyl-2,3,4,5-tetrahydro-1H-1-benzazepine patients as compared to the general population reported in the (OPC-41061): A potent, Orally Active Vasopressin Non-pep National Health and Nutrition Examination Survey. Since 40 tide Arginine Vasopressin V2 Receptor Antagonist, Bioor low levels of HDL cholesterol increase the risk of atheroscle ganic and Medicinal Chemistry 7 (1999) 1743-1754. rosis, methods for elevating plasma HDL cholesterol would There have also been several reports of small molecule be therapeutically beneficial for the treatment of cardiovas CETP inhibitors. Barrret et al. (J. Am. Chem. Soc., 188, cular disease including, but not limited to, atherosclerosis, 7863, (1996)) and Kuo et al. (J. Am. Chem. Soc., 117, 10629, CHD, stroke, and peripheral vascular disease. 45 (1995)) describe cyclopropan-containing CETP inhibitors. Cholesterol ester transfer protein (CETP) is a 74KD gly Pietzonka et al. (Biorg. Med. Chem. Lett. 6, 1951 (1996)) coprotein that facilitates the exchange of cholesterol esters in describe phosphanate-containing analogs as CETP inhibi HDL for triglycerides in triglyceride-rich lipoproteins (A. R. tors. Coval et al. (Bioorg. Med. Chem. Lett. 5, 605, (1995)) Tallet. al., (1999) 1999 George Lyman Duss Memorial Lec describe Wiedendiol-A and -B related sesquiterpines as ture: Lipid transfer proteins, HDL metabolism and athero 50 CETP inhibitors. Japanese Patent Application No. genesis. Arterio. Thromb. Vasc. Biol. 20:1185-1188.). The net 10287662-A describes polycyclic, non-amine containing, result of CETP activity is a lowering of HDL cholesterol and polyhydroxylic natural compounds possessing CETP inhibi an increase in LDL cholesterol. This effect on lipoprotein tion properties. Lee et al. (J. Antibiotics, 49, 693-96 (1996)) profile is believed to be proatherogenic, especially in Subjects describe CETP inhibitors derived from an insect fungus. whose lipid profile constitutes an increased risk for CHD. 55 Buschet al. (Lipids, 25, 216-220 (1990)) describe cholesteryl Niacin can significantly increase HDL, but has serious tol acetyl bromide as a CETP inhibitor. Morton and Zilversmit eration issues that reduce compliance. Currently marketed (J. Lipid Res., 35,836-47 (1982)) describe that p-chloromer fibrates and HMG CoA reductase inhibitors raise HDL cho curiphenyl sulfonate, p-hydroxymercuribenzoate and ethyl lesterol only modestly (~10-12%). As a result, there is a mercurithiosalicylate inhibit CETP. Connolly et al. (Bio significant unmet medical need for a well-tolerated agent 60 chem.
Load more

Recommended publications
  • A Calix[4]Arene Based Boronic Acid Catalyst for Amide Bond Formation: Proof of Principle Study
    The Free Internet Journal Paper for Organic Chemistry Archive for Arkivoc 2018, part v, 221-229 Organic Chemistry A calix[4]arene based boronic acid catalyst for amide bond formation: proof of principle study Asslly Tafara Mafaune and Gareth E. Arnott* Department of Chemistry and Polymer Science, Stellenbosch University, Private Bag X1, Matieland, South Africa Email: [email protected] Received 01-23-2018 Accepted 04-14-2018 Published on line 06-25-2018 Abstract A calix[4]arene boronic acid was synthesized and tested for catalysis in amide formation. The results were positive and paved the way for future designs, even though protodeboronation was observed under the conditions employed. Keywords: Amide bond catalysis, calix[4]arene boronic acid, protodeboronation DOI: https://doi.org/10.24820/ark.5550190.p010.492 Page 221 ©ARKAT USA, Inc Arkivoc 2018, v, 221-229 Mafaune, A. T. et al. Introduction The importance of amide bonds to human kind cannot be overemphasized; they are ubiquitous in nature and indispensable in chemical applications. They can be found in compounds such as the polymers that make our lives easier; the insecticides and agrochemicals that ensure that we have food on our tables; and most notably in the pharmaceutical drugs that help us live longer. Amide bonds are also part of the building blocks of biological systems, linking together amino acid units forming peptides, proteins and enzymes. The amide is arguably the most important functional group in chemistry and it also happens to be the most frequently synthesized in medicinal chemistry.1 Because of the versatility and importance of the amide bond, catalytic direct amide formation has been highlighted as a top priority reaction from a green chemistry viewpoint.
    [Show full text]
  • Phenyl Replacement Reactions: Solvent Effects on Reactions of Boroxines with Primary Amines
    Phenyl Replacement Reactions: Solvent Effects on Reactions of Boroxines with Primary Amines A thesis presented to the faculty of the Graduate School of Western Carolina University in partial fulfillment of the requirements for the degree of Master of Science in Chemistry. By Nicholas John Wilcox Director: Dr. William R. Kwochka Associate Professor of Chemistry Chemistry Department Committee Members: Dr. Channa De Silva, Chemistry Dr. Brian Dinkelmeyer, Chemistry March 2015 TABLE OF CONTENTS Page List of Figures ......................................................................................................................... iii List of Schemes ...................................................................................................................... vi Abstract................................................................................................................................... vii Chapter One: Introduction ....................................................................................................... 1 1.1 Background ...................................................................................................... 1 1.2 Complexes created by dative bonds ................................................................ 3 Chapter Two: Results and Discussion ..................................................................................... 7 2.1 Displacement and Complexation Reactions ..................................................... 7 Chapter Three: Conclusion ....................................................................................................
    [Show full text]
  • 1 Structure, Properties, and Preparation of Boronic Acid Derivatives Overview of Their Reactions and Applications Dennis G
    j1 1 Structure, Properties, and Preparation of Boronic Acid Derivatives Overview of Their Reactions and Applications Dennis G. Hall 1.1 Introduction and Historical Background Structurally, boronic acids are trivalent boron-containing organic compounds that possess one carbon-based substituent (i.e., a CÀB bond) and two hydroxyl groups to fill the remaining valences on the boron atom (Figure 1.1). With only six valence electrons and a consequent deficiency of two electrons, the sp2-hybridized boron atom possesses a vacant p-orbital. This low-energy orbital is orthogonal to the three substituents, which are oriented in a trigonal planar geometry. Unlike carbox- ylic acids, their carbon analogues, boronic acids, are not found in nature. These abiotic compounds are derived synthetically from primary sources of boron such as boric acid, which is made by the acidification of borax with carbon dioxide. Borate esters, one of the key precursors of boronic acid derivatives, are made by simple dehydration of boric acid with alcohols. The first preparation and isolation of a boronic acid was reported by Frankland in 1860 [1]. By treating diethylzinc with triethylborate, the highly air-sensitive triethylborane was obtained, and its slow oxidation in ambient air eventually provided ethylboronic acid. Boronic acids are the products of a twofold oxidation of boranes. Their stability to atmospheric oxidation is considerably superior to that of borinic acids, which result from the first oxidation of boranes. The product of a third oxidation of boranes, boric acid, is a very stable and relatively benign compound to humans (Section 1.2.2.3). Their unique properties and reactivity as mild organic Lewis acids, coupled with their stability and ease of handling, are what make boronic acids a particularly attractive class of synthetic intermediates.
    [Show full text]
  • Boronic Acids
    Boronic Acids Boronic acids and their derivatives are among the most useful classes of organoboron molecules. Unlike many organometallic derivatives and most organoboranes, boronic acids are usually stable to air and moisture, and are of relatively low toxicity and environmental impact. The reactions of boronic acids can be divided into two categories according to whether the boron-oxygen or the carbon-boron bonds are involved. Reactions involving the B-O bonds Boroxine formation Most boronic acids readily undergo dehydration to form cyclic trimeric anhydrides (boroxines) (Scheme 1). This tends to occur spontaneously at room temperature, so that it is difficult to obtain the acid free from the anhydride. Since in almost all cases, both will undergo the required reaction, they can usually be regarded as equivalent. Scheme 1 Boronate formation The ease with which boronic acids react with diols, with loss of water, to give cyclic boronic esters (boronates) has led to their application in a number of areas, especially in the carbohydrate field. Protection of diols One of the main applications of boronic acids has been as reagents for protection and derivatization of 1,2- and 1,3-diols as boronates (1,3,2-dioxaborolanes and 1,3,2-dioxa- borinanes), particularly in carbohydrate chemistry.1 These have been widely used as volatile derivatives for GC and GC-MS purposes. The boronate derivatives are formed simply by stirring the boronic acid and diol together at ambient temperature, by warming, or, if necessary, with azeotropic removal of water. Usually cleavage occurs readily under hydrolytic conditions, by exchange with a glycol,2 or by treatment with hydrogen peroxide.3 Hindered boronic esters, such as those of pinacol, may be relatively stable to hydrolysis, and can often be purified by chromatography.
    [Show full text]
  • New Conducting Salts for Rechargeable Lithium-Ion Batteries
    New Conducting Salts for Rechargeable Lithium-Ion Bateries INAUGURALDISSERTATION zur Erlangung des Doktorgrads der Fakultät für Chemie und Pharmazie der Albert-Ludwigs-Universität Freiburg im Breisgau vorgelegt von Michael Rohde aus Freiburg im Breisgau 2014 Vorsitzender des Promotionsausschusses: Prof. Dr. Torsten Koslowski Referent: Prof. Dr. Ingo Krossing Korreferent: Prof. Dr. Caroline Röhr Datum der mündlichen Prüfung: 30.03.2014 Diese Arbeit wurde im Zeitraum von Oktober 2010 bis Februar 2014 am Freiburger Materialforschungszentrum der Albert-Ludwigs-Universität in Freiburg im Breis- gau unter Anleitung von Prof. Dr. Ingo Krossing angefertigt. Teile dieser Arbeit enthalten Ergebnisse, die im Rahmen von Bachelorarbeiten (Alexander Norow 08.2011, Verena Leppert 08.2012, Lutz Miensopust 05.2013 und Marcel Schorpp 07.2013) im Arbeitskreis von Prof. Krossing unter meiner Anleitung angefertigt wurden. „achtzehn?“ „weg.“ „weg!“ „Karo.“ „Kontra!“ VII Danksagung Ich danke allerherzlichst meinem Doktorvater Prof. Ingo Krossing für das Bereitstellen des spannenden Temas innerhalb dieser Industriekooperation, seine ausgezeichnete Betreuung über all die Jahre, seine Motivationsfähigkeit und die bei dieser Arbeit ge- lassenen Freiheiten. Ich möchte mich sehr herzlich bedanken bei der Korreferentin Prof. Caroline Röhr für die Übernahme der Zweitkorrektur dieser Arbeit, dem Dritprüfer Prof. Michael Fiederle, meinen Laborkollegen Michel Panzer und Christoph Schulz für die geniale Zeit, dem Gruppenleiter Philipp Eiden für seine Geduld bei meinen vielen Fragen, den Bachelorstudenten Alexander Norow, Verena Leppert, Lutz Miensopust und Marcel Schorpp für die Unterstützung im Labor, den Partnern von der BASF Dr. Michael Schmidt, Dr. Arnd Garsuch und Dr. Günter Semrau für die produktiven Projektrefen und angenehme Zusammenarbeit, Stefanie Kuhl für Hilfe bei allen organisatorischen Dingen, die tolle Zeit auf den Sci- ence-Days und die Zeit im FMF oder auch außerhalb.
    [Show full text]
  • Boronic Acids
    Boronic Acids Boronic Acids www.alfa.com INCLUDING: • Boronic Esters • Oxazaborolidine Reagents • Coupling and Hydroboration Catalysts • Phosphine Ligands • Borylation Reagents www.alfa.com Where Science Meets Service Quality Boronic Acids from Alfa Aesar Alfa Aesar is known worldwide for a variety of chemical compounds used in research and development. Recognized for purity and quality, our products and brands are backed by technical and sales teams dedicated to providing you the best service possible. In this catalog, you will find details on our line of boronic acids, esters and related compounds, which are manufactured to the same exacting standards as our full offering of over 33,000 products. Also included in this catalog is a 28-page introduction to boronic acids, their properties and applications. This catalog contains only a selection of our wide range of chemicals and materials. Also included is a selection of novel coupling catalysts and ligands. Many more products, including high purity metals, analytical products, and labware are available in our main catalog or online at www.alfa.com. Table of Contents About Us _____________________________________________________________________________ II How to Order/General Information ____________________________________________________ III Introduction __________________________________________________________________________ 1 Alkenylboronic acids and esters _____________________________________________________ 29 Alkylboronic acids and esters ________________________________________________________
    [Show full text]
  • The Metallomimetic Chemistry of Boron Marc-André Légaré,A,B
    The Metallomimetic Chemistry of Boron Marc-André Légaré,a,b,* Conor Pranckevicius,a,b,* Holger Braunschweiga,b a Institute for Inorganic Chemistry, Julius-Maximilians-Universität Würzburg, Am Hubland, 97074 Würzburg (Germany). b Institute for Sustainable Chemistry & Catalysis with Boron, Julius-Maximilians- Universität Würzburg, Am Hubland, 97074 Würzburg (Germany). * These authors contributed equally Abstract: The study of main-group molecules that behave and react similarly to transition metal (TM) complexes has attracted significant interest in the recent decades. Most notably, the attractive idea of eliminating the all-too-often rare and costly metals from catalysis has motivated efforts to develop main-group-element-mediated reactions. Main-group elements, however, lack the electronic flexibility of many TM complexes that arise from combinations of empty and filled d-orbitals and that seem ideally suited to bind and activate many substrates. In this Review, we look at boron, an element which, despite its non-metal nature, low atomic weight, and relative redox staticity has achieved great milestones in terms of TM-like reactivity. We show how in inter-element cooperative systems, diboron molecules and hypovalent complexes, the fifth element can acquire a truly metallomimetic character. As we discuss, this character is particularly strikingly demonstrated by the reactivity of boron-based molecules with H2, CO, alkynes, alkenes and even with N2. 1.1. Introduction The transition elements are defined by their d-orbital sub-shell which has the unique situation of being partially filled.1 These d-orbitals, which are part of the valence shell of the transition metals, have become the salient feature of their chemistry and give them a unique place in the periodic table and in the realms of scientific interests and applications.
    [Show full text]
  • UC Santa Cruz Electronic Theses and Dissertations
    UC Santa Cruz UC Santa Cruz Electronic Theses and Dissertations Title OBSERVATIONS IN REACTIVITY BETWEEN BH CONTAINING COMPOUNDS AND ORGANOMETALLIC REAGENTS: SYNTHESIS OF BORONIC ACIDS, BORONIC ESTERS, AND MAGNESIUM HYDRIDES Permalink https://escholarship.org/uc/item/113107h0 Author Clary, Jacob William Publication Date 2012 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California UNIVERSITY OF CALIFORNIA SANTA CRUZ OBSERVATIONS IN REACTIVITY BETWEEN BH CONTAINING COMPOUNDS AND ORGANOMETALLIC REAGENTS: SYNTHESIS OF BORONIC ACIDS, BORONIC ESTERS, AND MAGNESIUM HYDRIDES A dissertation submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY AND BIOCHEMISTRY by Jacob William Clary March 2012 The Dissertation of Jacob W. Clary is approved: Professor Bakthan Singaram, Advisor Professor Rebecca Braslau, Chair Professor Claude Bernasconi Tyrus Miller Vice Provost and Dean of Graduate Studies Copyright © by Jacob W. Clary 2012 ii TABLE OF CONTENTS LIST OF FIGURES viii LIST OF SCHEMES x LIST OF TABLES xii ABSTRACT xviii DEDICATION AND ACKNOWLEDGEMENTS xv CHAPTER 1. Review of Boronic Acid Synthesis and Applications 1 1.1 Introduction 2 1.1.1 Nomenclature of Boronic Acids 3 1.1.2 Properties of Boronic Acids 5 1.1.3 Analysis of Boronic Acids 7 1.2 Boronic Acids in Organic Chemistry 9 1.2.1 Suzuki-Miyaura C-C Cross-Coupling 9 1.2.1.1 Applications of the Suzuki-Miyaura Cross-Coupling Reaction 11 1.2.1.2 Mechanism of the Suzuki-Miyaura Cross-Coupling 15 1.2.2 Stereoselective Suzuki Cross-Coupling 16 1.2.3 C-N and C-O Cross-Coupling Reactions with Boronic Acids 23 1.2.4 Biological and Medicinal Applications 26 1.3 Synthesis of Boronic Acids 31 1.3.1 Transmetallation of Grignard and Organolithium Reagent 32 iii 1.3.2 Cross-coupling Reaction of Bis(pinacolato)diboron and Pinacolborane 34 1.3.3 C-H Activation 40 1.4.
    [Show full text]
  • Boronic Acid Building Blocks: Tools for Self Assembly
    View Online FEATURE ARTICLE www.rsc.org/chemcomm | ChemComm Boronic acid building blocks: tools for self assembly Ryuhei Nishiyabu,a Yuji Kubo,*a Tony D. James*b and John S. Fosseycd Received 30th July 2010, Accepted 3rd November 2010 DOI: 10.1039/c0cc02921a Dynamic covalent functionality has been acknowledged as a powerful tool for the construction of organised architectures, the reversible nature thermodynamically facilitates self-control and self-correction. The use of boronic acids complexation with diols and their congeners has already shown great promise in realising and developing reversible boron-containing multicomponent systems with dynamic covalent functionality. The structure-directing potential has lead to the development of a variety of self-organisation involving not only macrocycles, cages and capsules, but also porous covalent organic frameworks and polymers. Structure controls as well as remarkable synthesis are highlighted in this feature article. 1. Introduction increase in the applications of boronic acid based systems in self-assembly4 sensing,5 and separation science,6 recent The first synthesis of an organoboron compound, ethylboronic developments pertaining to self assembly are discussed herein. acid was reported by Frankland in 1860.1 Some twenty years after dichlorophenyl borane was reported by Michaelis and 1.1 Scope of article Becker, which on hydrolysis allowed phenylboronic acid to be prepared.2 Subsequently Grignard reagents were used with In this feature article recent developments in the boronic acid trialkyl
    [Show full text]
  • 1980 Synthesis and Structural Features of Hydrogen-Bonded
    Iğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi, 11(3): 1980-1989, 2021 Journal of the Institute of Science and Technology, 11(3): 1980-1989, 2021 ISSN: 2146-0574, eISSN: 2536-4618 Fizik / Physics DOI: 10.21597/jist.857611 Araştırma Makalesi / Research Article Geliş tarihi / Received: 10.01.2021 Kabul tarihi / Accepted: 25.03.2021 Atıf İçin: Üstündağ FD, Güngör E, Subaşat Kara H, 2021. Trifenilboroksin Katyonu ve Pt(SCN)4 Anyon Tuzu Tektonlarının Kombinasyonuna Dayanan Hidrojen Bağlı Ağların Sentezi ve Yapısal Özellikleri. Iğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi, 11(3): 1980-1989. To Cite: Ustundag FD, Gungor E, Subasat Kara H, 2021. Synthesis and Structural Features of Hydrogen-Bonded Networks Based on The Combination of Tectons Triphenylboroxine Cation and Pt(SCN)4 Anion Salts. Journal of the Institute of Science and Technology, 11(3): 1980-1989. Synthesis and Structural Features of Hydrogen-Bonded Networks Based on The Combination of Tectons Triphenylboroxine Cation and Pt(SCN)4 Anion Salts Fumet Duygu USTUNDAG1, Elif GUNGOR2, Hulya KARA SUBASAT3* ABSTRACT: In this work, a new compound [C15H16B3N3O5].[Pt(SCN)4].2(H2O] (1) has been synthesized and structurally characterized. The compound (1) crystallizes in monoclinic, space group 3 P21/c a=10.443 Å, b= 24.918 Å, c= 15.048 Å, 훼=90 , β=133.945 , γ=90 , V=2819.4 Å , Z=4. The use of molecular tecton (building block) able to form thiocyano-based hydrogen-bonded synthons (OH···SCN) to synthesize a diverse range of crystal structures is described. In the crystal structure, molecules are linked by intermolecular SCN···HN and BO···HN hydrogen bonds, forming a three- dimensional network.
    [Show full text]
  • Structure and Properties of 1,3-Phenylenediboronic Acid: Combined Experimental and Theoretical Investigations
    crystals Article Structure and Properties of 1,3-Phenylenediboronic Acid: Combined Experimental and Theoretical Investigations Agnieszka Adamczyk-Wo´zniak 1,*, Michał K. Cyra ´nski 2, Krzysztof Durka 1 , Jan T. Gozdalik 1, Paulina Klimentowska 2, Rafał Rusiecki 1,3, Andrzej Sporzy ´nski 1 and Dorota Zarzecza ´nska 4 1 Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-664 Warsaw, Poland; [email protected] (K.D.); [email protected] (J.T.G.); [email protected] (R.R.); [email protected] (A.S.) 2 Faculty of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland; [email protected] (M.K.S.); [email protected] (P.K.) 3 Adamed Pharma S.A., Pie´nków, Adamkiewicza 6A, 05-152 Czosnów, Poland 4 Faculty of Chemistry, University of Gda´nsk,Wita Stwosza 63, 80-308 Gda´nsk,Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-22-234-6147; Fax: +48-22-628-2741 Received: 16 January 2019; Accepted: 15 February 2019; Published: 19 February 2019 Abstract: The structure and properties of 1,3-phenylenediboronic acid are reported. Molecular and crystal structures were determined by single crystal as well as by powder X-ray diffraction methods. Acidity constant, thermal behavior, and NMR characterization of the title compound were also investigated. In addition to the experimental data, calculations of rotational barrier and intermolecular interaction energies were performed. The compound reveals a two-step acid–base equilibrium with different pKa values. TGA and DSC measurements show a typical dehydration reaction with formation of boroxine.
    [Show full text]
  • Enantioselective Desymmetrisation of Imides Using Oxazaborolidine
    Enantioselective Desymmetrisation of Imides Using Oxazaborolidine Catalysts Derived from cis- 1-amino-indan-2-ol A Dissertation Submitted for the Degree of Doctor of Philosophy By Ibrahim U Kutama University of Sheffield September 2014 Dedication This research work is dedicated to my wife Rukayya and my kids for their patience and perseverance and to my late father Usman Kutama who died just before this work was concluded. May Allah have mercy on his soul. ii Contents Contents iii Declaration v Publication vi Acknowledgements vii Abbreviations viii Abstract x 1. Introduction 1 1.1 Chirality 1 1.2 Asymmetric synthesis 1 1.2.1 Chiral reagent 2 1.2.2 Chiral auxiliary 3 1.2.3 Chiral catalyst 5 1.3 Oxazaborolidines 9 1.3.1 History 9 1.3.2 Mechanism 12 1.4 Enantioselective desymmetrisation 14 1.4.1 Background 14 1.4.2 Enantioselective reduction of imides 17 1.4.3 Enantioselective reduction of imides using oxazaborolidines 24 1.5 Aims 29 2. Desymmetrisation of maleimides 32 2.1 Synthesis and desymmetrisation of anthracene maleimides 32 2.1.1 Background 32 2.1.2 Synthesis of anthracene-maleimide cycloadducts 33 2.1.3 Desymmetrisation of anthracene-maleimide cycloadducts 34 2.1.4 Stereoablative upgrade of enantioselectivity 37 2.1.5 Conclusion 40 3. Synthesis of pyrrolam A 41 3.1 Investigation towards the synthesis of pyrrolam A 41 iii 3.2 Synthesis of pyrrolam A 47 3.3 Conclusion 52 4. Desymmetrisation of glutarimides 53 4.1 Background 53 4.2 Synthesis of glutarimides 53 4.2.1 Synthesis of 3-phenyl glutarimides 53 4.3 Desymmetrisation of 3-phenyl glutarimides 54 4.3.1 Desymmetrisation of N-PMP glutarimide 55 4.3.2 Desymmetrisation of N-Bn glutarimides 59 4.4 Synthesis and desymmetrisation of 3-substituted glutarimides 63 4.5 Establishing stereochemistry 68 4.6 Conclusion 71 4.7 Future work 71 5.
    [Show full text]